肺炎球菌ワクチン：市場予測（2022年～2027年）

世界の肺炎球菌ワクチンの市場規模は、2020年に99億6,200万米ドルとなり、予測期間中に6.97％のCAGRで拡大し、2027年に159億6,300万米ドルになると予測されています。

当レポートでは、肺炎球菌ワクチンの世界市場を調査し、市場規模や予測、市場の促進要因および課題、市場動向、セグメント別の市場分析、競合情勢、主要企業のプロファイルなどの体系的な情報を提供しています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション

第2章 調査手法

• 調査データ
• 仮定

第3章 エグゼクティブサマリー

• 調査のハイライト

第4章 市場力学

• 市場促進要因
• 市場抑制要因
• ポーターのファイブフォース分析
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• 業界のバリューチェーン分析

第5章 世界の肺炎球菌ワクチン市場分析：タイプ別

• イントロダクション
• 結合型ワクチン
• 多糖類ワクチン

第6章 世界の肺炎球菌ワクチン市場分析：用途別

• イントロダクション
• 定期予防接種
• 病気/感染症の予防接種

第7章 世界の肺炎球菌ワクチン市場分析：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
  • その他
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • その他
• 中東とアフリカ
  • サウジアラビア
  • イスラエル
  • その他
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • インドネシア
  • 台湾
  • タイ
  • その他

第8章 競合情勢と分析

• 主要企業と戦略分析
• 新興企業と市場の有利性
• 合併、買収、合意、およびコラボレーション
• ベンダー競争力マトリックス

第9章 企業プロファイル

• Pfizer
• GSK
• Merck
• AstraZeneca
• Serum Institute of India Pvt Ltd

The global pneumococcal vaccines market is projected to witness a CAGR of 6.97% during the forecast period to reach a market size of US$15.963 billion by 2027, increasing from US$9.962 billion in 2020.

Introduction

Vaccines that help prevent pneumococcal disease caused by Streptococcus pneumoniae bacteria are classified as pneumococcal vaccines. Immunization is one of the widely accepted forms against the disease.

Market Drivers.

Pneumococcal diseases are most common in younger children; however, adults and the elderly are more prone to pneumococcal contaminations and even death. Pneumonia vaccines are primarily given to children under two years and adults 65 years and older. The regular vaccination programs under the national policy are aiding the market to grow. Secondly, the rising awareness against pneumonia, directives launched by WHO and UNICEF, and increasing government support assist the expansion of the market in the current scenario.

By type, the pneumococcal conjugate vaccine segment is the most significant contributor to the global pneumonia vaccine market and is expected to maintain its dominant position throughout the analysis period. Geographically, the Asia-Pacific region showcases the highest growth potential due to changing health sectors and efforts led by the international organization, while North America continues to dominate the market.

Growth Factors.

• Growing incidence of childhood pneumonia.

Among all the infectious diseases prevalent among children, pneumonia has the highest share of fatalities in children. More than 800 thousand children under the age of five lose their lives every year due to pneumonia, while the number is around 2.2 thousand per day. Around 153 thousand of those children are newborns. According to data from UNICEF, 1,400 cases per 100,000 children suffer from pneumonia every year, which makes it 1 out of 71 children. The South Asian region has the highest incidence with 2,500 cases per 100,000 children, while the West and Central African region has an incidence rate of 1,620 cases per 100,000 children. These numbers are creating an alarming situation to combat child mortality rates which is expanding the vaccines market to increase its production capacity and spread its reach.

• Raising awareness and policies.

International organizations like WHO, UNICEF, and UNDP, in conjunction with the national government, are working to bring down the pneumonia infection rates, especially among the children and older generation who are more susceptible to such diseases. As such, the government of India launched 2017 the pneumococcal conjugate vaccine (PCV) into its national immunization program. These plans and policies boast the vaccines market with novel products being introduced and expansion of the existing product portfolios.

Restraints.

The high cost involved in the production of vaccines and the long duration of the process of production is challenging factors for market growth. However, the government subsidies on vaccine production and funds released by international organizations are helping to clear the hindrances of the path.

Impact of COVID-19 on the Pneumococcal Vaccines Market

The pandemic had an unforeseen effect on the vaccination market, and the impact on the pneumococcal vaccine market is no different. At first, routine vaccination decreased due to the pandemic. However, later studies indicated that the COVID-19 pandemic increased the need for pneumococcal vaccination, causing shipping restrictions on pneumococcal vaccines, which may cause a shortage of vaccines during a pandemic.

Competitive Insights.

The market leaders for the Global Pneumococcal Vaccines Market are Pfizer, GSK, Merck Serum Institute of India Pvt Ltd, and AstraZeneca. The recent developments by the key players include:

• In 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) approved their pneumonia vaccine named PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine). The vaccine was developed by Pfizer for adults ages 18 years and older in order to help the body fight pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes.
• Merck's pneumonia vaccine called VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine), which was specifically developed for adults 18 years of age and older to help the body fight Streptococcus pneumoniae serotypes, got the approval of the U.S. Food and Drug Administration (FDA)
• In 2020, Serum Institute announced it had developed a pneumonia vaccine named PNEUMOSIL by collaborating with PATH and Bill and Melinda Gates Foundation for more than a decade.

Segmentation:

• By Type

Conjugate vaccines

Polysaccharide vaccines

• By Application

Routine Vaccination

Vaccination for Disease/ Infection

• By Geography

North America

• USA
• Canada
• Mexico

South America

• Brazil
• Argentina
• Others

Europe

• UK
• Germany
• France
• Italy
• Spain
• Others

Middle East and Africa

• Saudi Arabia
• Israel
• Others

Asia Pacific

• Japan
• China
• India
• Indonesia
• Taiwan
• Thailand
• Others

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition
• 1.2. Market Segmentation

2. Research Methodology

• 2.1. Research Data
• 2.2. Assumptions

3. Executive Summary

• 3.1. Research Highlights

4. Market Dynamics

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porters Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. The Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. Global Pneumococcal Vaccines Market Analysis, By Type

• 5.1. Introduction
• 5.2. Conjugate vaccines
• 5.3. Polysaccharide vaccines

6. Global Pneumococcal Vaccines Market Analysis, By Application

• 6.1. Introduction
• 6.2. Routine Vaccination
• 6.3. Vaccination for Disease/ Infection

7. Global Pneumococcal Vaccines Market Analysis, By Geography

• 7.1. Introduction
• 7.2. North America 
  • 7.2.1. United States
  • 7.2.2. Canada
  • 7.2.3. Mexico 
  • 7.2.4. Others 
• 7.3. South America 
  • 7.3.1. Brazil
  • 7.3.2. Argentina 
  • 7.3.3. Others
• 7.4. Europe 
  • 7.4.1. United Kingdom
  • 7.4.2. Germany 
  • 7.4.3. France 
  • 7.4.4. Italy 
  • 7.4.5. Spain
  • 7.4.6. Others
• 7.5. Middle East and Africa 
  • 7.5.1. Saudi Arabia
  • 7.5.2. Israel 
  • 7.5.3. Others 
• 7.6. Asia Pacific 
  • 7.6.1. Japan
  • 7.6.2. China 
  • 7.6.3. India
  • 7.6.4. Indonesia
  • 7.6.5. Taiwan
  • 7.6.6. Thailand 
  • 7.6.7. Others 

8. Competitive Intelligence

• 8.1. Major Players and Strategy Analysis
• 8.2. Emerging Players and Market Lucrative
• 8.3. Mergers, Acquisition, Agreements, and Collaborations
• 8.4. Vendor Competitiveness Matrix

9. Company Profiles

• 9.1. Pfizer
• 9.2. GSK
• 9.3. Merck
• 9.4. AstraZeneca
• 9.5. Serum Institute of India Pvt Ltd